Immunization with a Dominant-Negative Recombinant Herpes Simplex Virus (HSV) Type 1 Protects Against HSV-2 Genital Disease in Guinea Pigs

DSpace/Manakin Repository

Immunization with a Dominant-Negative Recombinant Herpes Simplex Virus (HSV) Type 1 Protects Against HSV-2 Genital Disease in Guinea Pigs

Citable link to this page

. . . . . .

Title: Immunization with a Dominant-Negative Recombinant Herpes Simplex Virus (HSV) Type 1 Protects Against HSV-2 Genital Disease in Guinea Pigs
Author: Brans, Richard; Yao, Feng

Note: Order does not necessarily reflect citation order of authors.

Citation: Brans, Richard, and Feng Yao. 2010. Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs. BMC Microbiology 10: 163.
Full Text & Related Files:
Abstract: Background: CJ9-gD is a novel dominant-negative recombinant herpes simplex virus type 1 (HSV-1) that is completely replication-defective, cannot establish detectable latent infection in vivo, and expresses high levels of the major HSV-1 antigen glycoprotein D immediately following infection. In the present study, CJ9-gD was evaluated as a vaccine against HSV-2 genital infection in guinea pigs. Results: Animals immunized with CJ9-gD developed at least 700-fold higher titers of HSV-2-specific neutralization antibodies than mock-immunized controls. After challenge with wild-type HSV-2, all 10 control guinea pigs developed multiple genital lesions with an average of 21 lesions per animal. In contrast, only 2 minor lesions were found in 2 of 8 CJ9-gD-immunized animals, representing a 40-fold reduction on the incidence of primary genital lesions in immunized animals (p < 0.0001). Immunization significantly reduced the amount and duration of viral shedding and provided complete protection against neurological symptoms, while 90% of mock-immunized animals succumbed due to the severity of disease. Importantly, immunized animals showed no signs of recurrent disease or viral shedding during a 60-days observation period after recovery from primary infection, and carried 50-fold less latent viral DNA load in their dorsal root ganglia than the surviving mock-vaccinated controls (p < 0.0001). Conclusions: Collectively, we demonstrate that vaccination with the HSV-1 recombinant CJ9-gD elicits strong and protective immune responses against primary and recurrent HSV-2 genital disease and significantly reduces the extent of latent infection.
Published Version: doi: 10.1186/1471-2180-10-163
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889954/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4875085

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters